The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells

Previous studies have suggested that histone methylation can modulate carcinogenesis and cancer progression. For instance, the histone methyltransferase SET and MYND domain containing 2 (SMYD2) is overexpressed in several types of cancer tissue. The aim of the present study was to determine whether...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncol Lett
Autores principales: Kojima, Machiko, Sone, Kenbun, Oda, Katsutoshi, Hamamoto, Ryuji, Kaneko, Syuzo, Oki, Shinya, Kukita, Asako, Kawata, Akira, Honjoh, Harunori, Kawata, Yoshiko, Kashiyama, Tomoko, Sato, Masakazu, Taguchi, Ayumi, Miyamoto, Yuichiro, Tanikawa, Michihiro, Tsuruga, Tetsushi, Nagasaka, Kazunori, Wada-Hiraike, Osamu, Osuga, Yutaka, Fujii, Tomoyuki
Formato: Artigo
Lenguaje:Inglês
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7471656/
https://ncbi.nlm.nih.gov/pubmed/32934721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2020.12014
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares